SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates potential short-term dips versus long-term bullish prospects, with some bracing for a possible weekend correction. Discussions include technical analysis, predictions of future price movements, and the impact of external factors like potential government regulations and macroeconomic conditions. Some traders are closely watching altcoins and memecoins while also weighing investment strategies around Bitcoin.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst a broad crypto dip, sparking discussions about market manipulation and potential buying opportunities. The community is weighing the impact of upcoming ETFs and regulatory developments against concerns about price suppression and the token's long-term potential. Some traders are looking for a dip to accumulate more XRP, while others are losing faith.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as traders discuss recent price volatility and potential manipulation, with some seeing buying opportunities amidst the overnight dips. Community members are weighing in on technical analysis, potential support levels, and the impact of large players. The conversation also includes speculation about upcoming catalysts and long-term price predictions for ETH.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as community members discuss a potential short squeeze, given the high short interest. However, some are pointing to insider selling and debating the company's valuation relative to its Bitcoin holdings. Sentiment is further influenced by potential AI ventures, broader market factors, and comparisons to other mining stocks.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members discuss its recent surge, potential for further growth, and comparisons to other quantum computing stocks like $QUBT and $IONQ. Some traders are taking profits, while others remain bullish, citing government contracts and long-term potential, while some express concerns about high valuation.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors monitor its correlation with Ethereum's price movements, particularly overnight dips, and anticipate potential strategic ETH acquisitions by the company. The community is actively discussing dilution possibilities and speculating on the impact of Tom Lee's investment strategies, while also eyeing potential mergers within the crypto space. Bullish sentiment persists, with some traders anticipating a breakout and significant gains, driven by the company's growing ETH holdings and positive technical indicators.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo ($OKLO) is trending due to a recent price target increase from Wedbush, fueling both excitement and skepticism. While some see it as a leader in a $10 trillion industry akin to early NVDA, others believe it's overvalued with no current product or revenue, drawing comparisons to meme stocks and potential future dilution. The community is debating its long-term potential versus short-term hype, with concerns about insider selling and an upcoming offering.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

Metsera is trending amid reports of a potential acquisition by Pfizer for $7.3 billion, fueling discussions about the increasing value of obesity and MASH-focused drug companies. The community speculates about potential competing offers and the implications for other players in the sector like $VKTX and $ALT. Some traders are focused on upcoming data releases, anticipating significant stock movement.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK.X is trending as community members rally around its satirical take on traditional retirement plans, with many expressing excitement about its potential. Fueling the conversation is the coin's recent growth and strong community engagement, as well as its positioning as an alternative to the conventional 401k. The coin is associated with the Solana blockchain.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending due to news of a significant private placement, leading to community discussions about dilution and its potential impact. Some traders are pointing out this could lead to a pullback, while others believe it signals continued momentum in the quantum computing sector. The community is also weighing the news against the backdrop of broader interest in quantum computing and potential government investment.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. government is widely expected to link Tylenol to autism, advising pregnant women against its use, Monday, according to media reports. The development is keeping retail investors on the edge for its maker, Kenvue, and associated company Johnson &amp; Johnson, according to Stocktwits data.Tylenol is an acetaminophen-based over-the-counter medicine for reducing pain, allergies, cold, and fever. The popular tablets are produced, marketed, and sold by Kenvue, which spun off from J&amp;J in 2023,&nbsp;and rake in about $1 billion annually, a high-single-digit percentage of the firm’s total revenue,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/stocks/kenvue-stock-tumbles-kennedys-pending-report-tylenol-autism">according</a> to a Morningstar analyst.U.S. officials&nbsp;are expected to hold a press conference on autism on Monday; in the run-up, President Donald Trump had said: "We think we found an answer to autism... There's obviously something really wrong, we think we know what that is."The Washington Post reported on the weekend that officials will promote the drug leucovorin as a potential autism treatment. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.Earlier this month, the Wall Street Journal reported U.S. health officials' internal view regarding Tylenol. The news sent Kenvue's shares down 9.4% on Sept. 5. Kenvue said on Sunday that "independent, sound science" shows taking acetaminophen does not cause autism."We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," the company said in a statement.Several Stocktwits users, on both Kenvue and J&amp;J&nbsp;streams, predicted steep declines for the stocks on Monday. Twenty-four-hour message volume on the tickers surging 300% and 150%, respectively.Retail sentiment for both KVUE and JNJ was ‘neutral’ at the time of writing, indicating significant levels of caution among traders ahead of Monday’s market open.<figure class="image"><img style="aspect-ratio:567/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_41_57_AM_png_e493de6988.webp" alt="Screenshot 2025-09-22 at 9.41.57 AM.png" width="567" height="71"><figcaption>KVUE sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:571/73;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_42_37_AM_png_11ece70092.webp" alt="Screenshot 2025-09-22 at 9.42.37 AM.png" width="571" height="73"><figcaption>JNJ sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure>"$JNJ 5-year chart looks like a heartbeat… she's gonna drop and flatline tomorrow," said a user.<stembedurl>https://stocktwits.com/TheDude5386/message/629455153</stembedurl>Another said: "$KVUE could be a buying opportunity if we see an overreaction."<stembedurl>https://stocktwits.com/Sigh_why/message/629453593</stembedurl>Kenvue's main brands include Tylenol, Motrin, Listerine, Neutrogena, Aveeno, and Band-Aid.<a href="https://stocktwits.com/symbol/KVUE">Kenvue shares</a> are down 14.1% year-to-date;&nbsp;<a href="https://stocktwits.com/symbol/JNJ">J&amp;J stock</a> is up 22%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-confirms-news-corp-s-murdochs-larry-ellison-michael-dell-lining-up-to-take-over-tik-tok-us/chDQBrbR3cR">Trump Confirms News Corp’s Murdochs, Larry Ellison, Michael Dell Lining Up To Take Over TikTok US</a>

Pain medications, which contain acetaminophen, are shown on April 14, 2015 in Chicago, Illinois. (Photo Illustration by Scott Olson/Getty Images)

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

Equity

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.


Top Wide-Moat Stocks Worth a Look for Sustainable Growth 

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Tylenol maker Kenvue Inc. (KVUE) reportedly met with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.According to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-12/kenvue-met-with-rfk-jr-in-bid-to-keep-tylenol-off-autism-list">report</a>, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.<a href="https://stocktwits.com/symbol/KVUE">Kenvue’s shares</a> were up 1.24% in Friday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory.Kenvue said in an emailed statement to Bloomberg that it engaged with the Health Secretary in a “scientific exchange” as it relates to the safety of its products. “We continue to believe that taking acetaminophen does not cause autism, and global health regulators, independent public health organizations, and medical professionals agree,” the company said, adding that acetaminophen is one of the most studied medications in history.Tylenol is a part of Kenvue’s self-care segment, which accounted for more than 40% of the company’s revenue in the second quarter (Q2). The company’s organic sales fell 4.2% during the quarter, which was due to “weak allergy and sun seasons in North America, trade inventory fluctuations in certain customers, and changes in shipment timing versus last year in China,” according to a statement from Kenvue.Last week, a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal noted the Department of Health and Human Services could link autism to the use of Tylenol in pregnancy. The HHS report is expected to be issued this month, it added.<a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> is down 11% year-to-date and 17% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-fed-rate-cuts-through-january/chw8AhGRdDi">Morgan Stanley Reportedly Expects 4 Rate Cuts Through January, Says Fed Will Aim To Arrive At Neutral Rates ‘More Decisively’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Tylenol Maker Kenvue Met With RFK Jr. In A Bid To Keep OTC Painkiller Off Autism List: Report

According to a Bloomberg report, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.

Bank of America stated that Kenvue (KVUE) is expected to be viewed as a “particularly attractive entry point” after the recent pullback in its stock following media reports that surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of its Tylenol drug to autism.Analyst Anna Lizzul said that the company's new CEO and CFO took the opportunity in August to reset expectations at earnings and sees its lowered 2025 guidance as "achievable," according to TheFly.Shares of <a href="https://stocktwits.com/symbol/KVUE">Kenvue</a> closed down 9.3% on Friday. Bank of America noted that given the current valuation discount to the average of household and personal care peers, the firm reiterates its ‘Buy’ rating and $25 price target as it sees a widening discount offering an attractive entry point.Retail sentiment on Kenvue dipped to ‘bullish’ from ‘extremely bullish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:807/107;" src="https://news.stocktwits-cdn.com/KVUE_sentiment_png_2b6f08c92e.webp" alt="KVUE sentiment.png" width="807" height="107"><figcaption>KVUE sentiment and message volume September 8, 2025, as of 8:30 am ET | Source: Stocktwits</figcaption></figure>Evercore ISI lowered its price target on Kenvue to $23 from $25 and maintained an ‘In Line’ rating, reflecting lower peer valuations and the premium Tylenol commands within Kenvue's portfolio. The firm noted that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, in an upcoming Health Department report, there would be findings expected to link autism risk to low folate levels and Tylenol use during pregnancy.&nbsp;Despite headline risks, a lack of definitive evidence linking Acetaminophen, the active ingredient in Tylenol, to autism may suggest limited long-term impact. Still, legal uncertainties could delay strategic moves, Evercore added.&nbsp;&nbsp;Kenvue shares have declined nearly 13% this year and approximately 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-sportswear-giant-got-added-to-jefferies-franchise-picks-list/chwWxLeRdrc">This Sportswear Giant Got Added To Jefferies’ Franchise Picks List – Find Out More</a>

Kenvue Seen As Attractive Buy By BofA After Stock Dip Following Report On Tylenol Autism Link

Evercore said that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.

Kenvue Seen As Attractive Buy By BofA After Stock Dip

Tylenol maker Kenvue (KVUE) dropped to a one-year low in afternoon trade on Friday after reports surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of the drug to autism.<a href="http://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> tumbled more than&nbsp;13%&nbsp;to&nbsp;$17.77, its lowest level since&nbsp;July 2024. On Stocktwits, retail sentiment around the company fell into ‘bearish’ territory from ‘neutral’ over the past day.&nbsp;Friday’s drop brings Kenvue’s year-to-date loss to over 17%. The stock has fallen 21% over the past 12 months.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, the Department of Health and Human Services (HHS) is likely to release its findings later this month. The upcoming Health Department report is expected to link autism risk to low folate levels and Tylenol use during pregnancy, people familiar with the matter told the publication.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. The active ingredient in Tylenol is acetaminophen, which is widely used as a pain reliever, including by pregnant women.&nbsp;The report said that research on its impact during pregnancy has produced mixed results. It cited that the American College of Obstetricians and Gynecologists found Tylenol to be safe for use during pregnancy. However, it advises women to consult with their doctors before taking any medication.Kennedy, meanwhile, has long promised to reveal the cause of autism. “By September, we will know what has caused the autism epidemic,” he&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bbc.com/news/articles/cj0z9nmzvdlo">said</a> during an April cabinet meeting with President Donald Trump.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bessent-says-fed-must-change-course-to-preserve-independence/chwI13sRdqQ">Bessent Reportedly Says Fed Must Change Course To Preserve Independence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Kenvue Stock Hits One-Year Low After Report Says HHS Will Link Tylenol Use In Pregnancy To Autism Risk

According to a report by The Wall Street Journal, the Department of Health and Human Services is likely to release its findings later this month. 

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kenvue (KVUE) Q2 Earnings Top Estimates

Kenvue (KVUE) delivered earnings and revenue surprises of +3.57% and -0.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Edgewell Personal Care (EPC) Misses Q3 Earnings and Revenue Estimates

Edgewell Personal (EPC) delivered earnings and revenue surprises of -8.91% and -4.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

The broader market reversed on Monday, recovering from the steep losses witnessed on Friday, on hopes of an&nbsp;interest rate cut. The Dow Industrials jumped nearly 600 points,&nbsp;and small-cap stocks outperformed the broader market, with the Russell 2000 Index increasing by 2.10%.Amid the rise in risk appetite, the S&amp;P 500 Index snapped a four-session decline, ending 1.47% higher.Earnings news continues to drive market activity, with more updates expected on Tuesday.<a href="https://stocktwits.com/symbol/PLTR">Palantir Technologies (PLTR)</a>After-hours move: +4.57%Trading volume: 17.39 millionPalantir stock took off in after-hours trading on Monday after the company reported a solid quarterly beat and raised its full-year guidance. Investors cheered the Alex-Karp-led company’s first-ever billion-dollar revenue quarter.&nbsp;Retail users of the Stocktwits platform relished the results, with sentiment flipping to ‘extremely bullish’ by late Monday from ‘bearish’ a day ago. The message volume also lifted to ‘extremely high’ levels.&nbsp;Palantir stock, which was up over 112% year-to-date by Monday’s close, is on track to hit fresh highs on Tuesday.<a href="https://stocktwits.com/symbol/KVUE">Kenvue (KVUE)</a>After-hours move: +1.22%Trading volume: 14.20 millionKenvue stock has been on investors’ radar as the consumer health company spun off from Johnson &amp; Johnson faces fundamental issues. The company has recently undergone a change in leadership and has also initiated a strategic review process.&nbsp;The stock gained momentum ahead of the company’s second-quarter results, due on Thursday before the market opens. Fiscal.ai-compiled consensus puts the company’s earnings per share (EPS) and revenue at $0,28 and $3.85 billion, respectively. This marks a decline from the year-ago $0.32 and $4 billion, respectively.&nbsp;The company is the maker of renowned healthcare product brands such as Tylenol and Band-Aid.On Stocktwits, retail sentiment toward the stock continues to languish at a ‘bearish’ level, with the message volume remaining ‘low.’Kenvue stock is up about 6% this year.<a href="https://stocktwits.com/symbol/AAPL">Apple (AAPL)</a>After-hours move: -0.05%Trading volume: 12.71 millionApple’s blowout third-quarter results did not ignite a rally in the stock as the soft July non-farm payrolls report played a spoilsport on Friday. The stock did not gain enough momentum on Monday, despite the broader market rally. The muted reaction reflected investor concerns about the impact of Trump tariffs and Apple's lag in adopting artificial intelligence.Bloomberg’s Mark Gurman said on Sunday that Apple is working on a stripped-down version of a standalone app, similar to ChatGPT, in-house.Apple stock is down 18.60% this year, despite the broader market gaining over 8%. Retail traders, however, are upbeat, with Stocktwits sentiment meter showing a reading relaying an ‘extremely bullish’ mood.<a href="https://stocktwits.com/symbol/INTC">Intel (INTEL)</a>After-hours move: flatTrading volume: 9.65 millionShares of struggling chipmaker Intel also saw brisk trading volumes in Monday’s extended hours. Late Monday, rating agency Fitch downgraded Intel’s “Long-Term Issuer Default Rating” (IDR) and senior unsecured ratings to 'BBB' from 'BBB+,' and affirmed its “Short-Term IDR and commercial paper rating at 'F2'. The Rating Outlook was set at Negative.The rating agency stated that the actions reflected its view that the demand environment would be more challenging than previously anticipated, thereby constraining profitability growth. It also expects the credit metrics to remain weak.Intel shares continued to attract ‘bearish’ sentiment among users of the Stocktwits platform, with the sour mood accompanied by ‘low’ volumes.The stock is down nearly 2.5% this year.<a href="https://stocktwits.com/symbol/NVDA">Nvidia (NVDA)</a>After-hours move: +0.37%Trading volume: 9.14 millionNvidia shares recovered from Friday’s sell-off and ended Monday’s session up 3.62% at $180, a record closing high. The stock, however, could not go past its intraday high of $183.30 in Monday’s session.The stock is likely to continue its winning run on Tuesday, thanks to Palantir’s strong results and Cathie Wood’s Ark Invest snapping up more than 23,000 Nvidia shares.Retail sentiment toward Nvidia stock tempered slightly to ‘bullish’ from ‘extremely bearish’ a day ago. The message volume remained at ‘high’ levels.The stock has gained a whopping 34% this year.The Jensen Huang-led company, which is riding high on its near-monopoly position in the AI chip market, is scheduled to report its quarterly results on Aug. 27. Traders may read the tea leaves from AI chip peer AMD’s (AMD) results due Tuesday after the market close and the management commentary.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-jones-nasdaq-futures-rise-on-palantir-boost-rate-cut-hopes/chrLW9YRdcg">Dow Jones, Nasdaq Futures Rise On Palantir Boost, Rate Cut Hopes — Trump Promises 'Many More Days Like This' In Stock Market</a>

Traders work on the floor of the New York Stock Exchange during afternoon trading on August 01, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Palantir, Kenvue, Apple, Intel, Nvidia: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Amid the rise in risk appetite, the S&P 500 Index snapped a four-session decline, ending 1.47% higher.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$18.57
Prev Close	$18.10
Open	$18.21
Dividend Yield	3.76%
50-Day Moving Average	$20.88
Beta	0.00
Avg. Volume	16.96M
PE Ratio	24.92

52-Week High	$25.17
52-Week Low	$17.15
Market Capitalization	$35.2B
EPS (Annual)	$0.5382
Price to Book	3.28
Revenue Per Employee	$702,545.45
Enterprise Value/EBITDA	N/A

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KVUE News

KVUE Kenvue Inc